Score Overview
Explore the 2021 public Archive ranking →
Where Takeda Pharmaceutical Co Ltd ADR has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- TAK
2019: 53.6% · 2021: 44.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-22 | $ 20.36 | — |
1 Year2025-10-22 | $ 13.61 | 49.60% |
5 Years2021-10-22 | $ 11.42 | 78.31% |
10 Years2016-10-21 | $ 14.42 | 41.19% |
All Time2008-10-27 | $ 9.38 | 117.07% |
| Period | Last Price2026-10-22 | 1 Year2025-10-22 | 5 Years2021-10-22 | 10 Years2016-10-21 | All Time2008-10-27 |
|---|---|---|---|---|---|
| Price | $ 20.36 | $ 13.61 | $ 11.42 | $ 14.42 | $ 9.38 |
| Return | — | 49.60% | 78.31% | 41.19% | 117.07% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in JPY
| Year | |||
|---|---|---|---|
| TTM | ¥ 4.66T | ¥ 182.13B | ¥ 527.58B |
| 2026 | ¥ 4.77T | ¥ 203.32B | ¥ 597.63B |
| 2025 | ¥ 4.58T | ¥ 107.92B | ¥ 405.58B |
| 2024 | ¥ 4.26T | ¥ 144.06B | ¥ 472.88B |
| 2023 | ¥ 4.02T | ¥ 317.01B | ¥ 553.70B |
| 2022 | ¥ 3.56T | ¥ 230.05B | ¥ 875.00B |
| 2021 | ¥ 3.19T | ¥ 376.00B | ¥ 1.00T |
| 2020 | ¥ 3.29T | ¥ 44.24B | ¥ 653.43B |
| 2019 | ¥ 2.09T | ¥ 109.12B | ¥ 725.36B |
| 2018 | ¥ 1.77T | ¥ 186.88B | ¥ 375.16B |
| 2017 | ¥ 1.73T | ¥ 114.94B | ¥ 376.13B |
| 2016 | ¥ 1.80T | ¥ 80.16B | ¥ 560.02B |
| 2015 | ¥ 1.77T | -¥ 145.77B | ¥ 713.42B |
| 2014 | ¥ 1.69T | ¥ 106.65B | ¥ 851.02B |
| 2013 | ¥ 1.55T | ¥ 131.24B | ¥ 561.82B |
| 2012 | ¥ 1.50T | ¥ 124.16B | ¥ 460.52B |
| 2011 | ¥ 1.41T | ¥ 247.86B | ¥ 874.21B |
| 2010 | ¥ 1.46T | ¥ 297.74B | ¥ 883.21B |
| 2009 | ¥ 1.53T | ¥ 234.38B | ¥ 758.78B |
Takeda Pharmaceutical Co Ltd ADR fundamental performance
Between 2021 and 2026, revenue grew from ¥ 3.19T to ¥ 4.77T and net income declined from ¥ 376.00B to ¥ 203.32B. Revenue increased in 4 of those 5 years; net income in 2.
Between 2016 and 2026, revenue grew from ¥ 1.80T to ¥ 4.77T and net income grew from ¥ 80.16B to ¥ 203.32B. Revenue increased in 8 of those 10 years; net income in 4.
Takeda Pharmaceutical Co Ltd ADR currently holds a 5-year HDB Score of 5.3 out of 10. How the HDB Score is calculated.
Membership
Continue TAK’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,119 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
